Andrew S Hyatt
Overview
Explore the profile of Andrew S Hyatt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
259
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hyatt A, Flores M, Le Cook B
Addict Behav
. 2024 Jun;
157:108095.
PMID: 38905902
Background: Cannabis use is on the rise, but it is unclear how use is changing among individuals with serious psychological distress (SPD) compared to the general population as well as...
2.
Hyatt A, Mulvaney-Day N, Chow C, Le Cook B, DeLisi L
Psychiatry Res
. 2024 Feb;
334:115785.
PMID: 38377800
Tobacco use has been established as a possible risk factor for psychosis, but the effect of electronic nicotine delivery systems (ex. nicotine vapes) has not been independently established. Using the...
3.
Hyatt A, Hasler V, Wilner E
Curr Opin Psychiatry
. 2022 May;
35(3):165-170.
PMID: 35579870
Purpose Of Review: Early intervention in first-episode psychosis (FEP) improves symptomatic and functional outcomes while programs last. However, these gains may not be sustained over time and not all individuals...
4.
Hyatt A, Tepper M, OBrien C
Psychiatr Serv
. 2021 Feb;
72(6):732-735.
PMID: 33593103
The rapid rise of value-based payment (VBP) models presents both new opportunities and challenges for behavioral health providers, especially in health systems that serve low-income and marginalized communities. This column...
5.
Nguyen P, Shin H, Yousefi K, Thompson D, Hornberger J, Hyatt A, et al.
Urology
. 2015 Jul;
86(1):35-40.
PMID: 26142578
Objective: To evaluate how a genomic classifier (GC) that predicts the risk of metastasis after prostatectomy would impact adjuvant treatment recommendations made by radiation oncologists and urologists. The 2 specialties...
6.
Mahal B, Cooperberg M, Aizer A, Ziehr D, Hyatt A, Choueiri T, et al.
Am J Med
. 2015 Feb;
128(6):609-16.
PMID: 25644324
Purpose: The long-term prostate cancer-specific survival for patients initially managed with active surveillance for low-risk prostate cancer ranges from 97% to 100%. We characterized factors that are associated with aggressive...
7.
Aizer A, Gu X, Chen M, Choueiri T, Martin N, Efstathiou J, et al.
J Natl Compr Canc Netw
. 2015 Jan;
13(1):61-8.
PMID: 25583770
Background: Evidence-based consensus guidelines recommend only observation for men with low-risk prostate cancer and life expectancy less than 10 years. This report describes the incidence, drivers, cost, and morbidity of...
8.
Ziehr D, Mahal B, Aizer A, Hyatt A, Beard C, D Amico A, et al.
Urol Oncol
. 2014 Oct;
33(1):18.e7-18.e13.
PMID: 25306287
Purpose: Definitive treatment of high-risk prostate cancer with radical prostatectomy or radiation improves survival. We assessed whether racial disparities in the receipt of definitive therapy for prostate cancer vary by...
9.
Ziehr D, Chen M, Zhang D, Braccioforte M, Moran B, Mahal B, et al.
BJU Int
. 2014 Aug;
116(3):358-65.
PMID: 25124891
Objectives: To determine if androgen-deprivation therapy (ADT) is associated with excess cardiac-specific mortality (CSM) in men with prostate cancer and no cardiovascular comorbidity, coronary artery disease risk factors, or congestive...
10.
Mahal B, Aizer A, Ziehr D, Hyatt A, Sammon J, Schmid M, et al.
Urology
. 2014 Jul;
84(2):386-92.
PMID: 24975710
Objective: To determine whether African Americans (AAs) with intermediate- to high-risk prostate cancer (PCa) receive similar treatment as white patients and whether any observed disparities are narrowing with time. Methods:...